Sandoz licences EG 12014 (trastuzumab biosimilar) from EirGenix

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar. This medicine (EG 12014) is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors.

The agreement between Sandoz and EirGenix, Inc, a biotechnology manufacturing and development company that aspires to provide high-quality medicines for individuals and society, aims to bring to market a proposed biosimilar trastuzumab. EirGenix will maintain responsibility for development and manufacturing, and Sandoz has the right to commercialize the medicine upon approval in all markets excluding China and Taiwan. According to the terms of the agreement, EirGenix will receive an upfront payment on signing, milestone payments, and is entitled to receive profit share payments for sales in the territories. This structure allows Sandoz to keep in-house resources focused on bringing forward a robust internal pipeline. The collaboration further expands the existing Sandoz oncology portfolio of four oncology biosimilar medicines, while enabling the company to further develop its strong hospital presence. Other specific terms of the agreement are confidential.